---
provider: asta
model: Asta Scientific Corpus Retrieval
cached: false
start_time: '2026-05-26T23:12:19.738467'
end_time: '2026-05-26T23:12:53.534041'
duration_seconds: 33.8
template_file: templates/hypothesis_deep_research.md
template_variables:
  disease_name: HER2-Positive Breast Cancer
  category: ''
  hypothesis_group_id: grb2_conformational_pivot_resistance_model
  hypothesis_label: GRB2 Conformational Pivot Resistance Model
  hypothesis_status: EMERGING
  hypothesis_yaml: "hypothesis_group_id: grb2_conformational_pivot_resistance_model\n\
    hypothesis_label: GRB2 Conformational Pivot Resistance Model\nstatus: EMERGING\n\
    description: GRB2 is a thermodynamic pivot point whose conformational state determines\
    \ whether HER2-driven\n  tumors funnel into cytoplasmic effector dominance, nuclear\
    \ RAD51-dependent replication-fork protection,\n  or PARPi-STING innate-immune\
    \ activation. Allosteric stabilization or PROTAC degradation of GRB2 would\n \
    \ select between these interactome states and modulate trastuzumab/TKI resistance.\
    \ This hypothesis is\n  distinguishable from the canonical effector model by predicting\
    \ that GRB2 perturbation produces different\n  phenotypes depending on which conformational\
    \ state is locked, not simply graded loss of adaptor function.\nevidence:\n- reference:\
    \ PMID:38459011\n  supports: SUPPORT\n  evidence_source: IN_VITRO\n  snippet:\
    \ Growth factor receptor-bound protein 2 (GRB2) is a cytoplasmic adapter for tyrosine\
    \ kinase\n    signaling and a nuclear adapter for homology-directed-DNA repair.\n\
    \  explanation: Dual cytoplasmic/nuclear GRB2 framing motivates the conformational-pivot\
    \ hypothesis as\n    distinct from the canonical effector model.\n- reference:\
    \ PMID:38459011\n  supports: SUPPORT\n  evidence_source: IN_VITRO\n  snippet:\
    \ In GRB2-depleted cells, PARP inhibitor (PARPi) treatment releases DNA fragments\
    \ from stalled\n    forks into the cytoplasm that activate the cGAS-STING pathway\
    \ to trigger pro-inflammatory cytokine\n    production.\n  explanation: Experimental\
    \ demonstration that loss of GRB2 fork-protection function produces a distinct\n\
    \    PARPi-STING vulnerability supports the pivot framing."
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    query_char_limit: 500
    paper_limit: 50
    snippet_limit: 20
    snippet_paper_limit: 50
    restrict_snippets_to_papers: false
    paper_fields: title,abstract,authors,year,url,venue,journal,tldr,publicationDate,citationCount,influentialCitationCount,externalIds
    publication_date_range: ''
    venues: ''
    inserted_before: ''
citation_count: 18
---

## Question

# Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** HER2-Positive Breast Cancer
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** grb2_conformational_pivot_resistance_model
- **Hypothesis Label:** GRB2 Conformational Pivot Resistance Model
- **Status in KB:** EMERGING

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: grb2_conformational_pivot_resistance_model
hypothesis_label: GRB2 Conformational Pivot Resistance Model
status: EMERGING
description: GRB2 is a thermodynamic pivot point whose conformational state determines whether HER2-driven
  tumors funnel into cytoplasmic effector dominance, nuclear RAD51-dependent replication-fork protection,
  or PARPi-STING innate-immune activation. Allosteric stabilization or PROTAC degradation of GRB2 would
  select between these interactome states and modulate trastuzumab/TKI resistance. This hypothesis is
  distinguishable from the canonical effector model by predicting that GRB2 perturbation produces different
  phenotypes depending on which conformational state is locked, not simply graded loss of adaptor function.
evidence:
- reference: PMID:38459011
  supports: SUPPORT
  evidence_source: IN_VITRO
  snippet: Growth factor receptor-bound protein 2 (GRB2) is a cytoplasmic adapter for tyrosine kinase
    signaling and a nuclear adapter for homology-directed-DNA repair.
  explanation: Dual cytoplasmic/nuclear GRB2 framing motivates the conformational-pivot hypothesis as
    distinct from the canonical effector model.
- reference: PMID:38459011
  supports: SUPPORT
  evidence_source: IN_VITRO
  snippet: In GRB2-depleted cells, PARP inhibitor (PARPi) treatment releases DNA fragments from stalled
    forks into the cytoplasm that activate the cGAS-STING pathway to trigger pro-inflammatory cytokine
    production.
  explanation: Experimental demonstration that loss of GRB2 fork-protection function produces a distinct
    PARPi-STING vulnerability supports the pivot framing.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.


## Output

# Asta Literature Retrieval: Mechanistic Hypothesis Search You are evaluating a specific disease mechanism hypothesis for the Disorder Mechanisms...

This report is retrieval-only and is generated directly from Asta results.

- Papers retrieved: 18
- Snippets retrieved: 20

## Relevant Papers

### [1] Gathering Evidence of Mechanisms
- Authors: Veli-Pekka Parkkinen, Christian Wallmann, Michael Wilde, B. Clarke, P. Illari et al.
- Year: 2018
- Venue: Unknown venue
- URL: https://www.semanticscholar.org/paper/06480fd932fc88915a4efb4c894a5ae4ed98452d
- DOI: 10.1007/978-3-319-94610-8_5
- Citations: 1
- Summary: Key issues include increased precision concerning the nature of the hypothesis being examined, attention to differences between the study population and the target population of the evidence assessors, and being alert for masking mechanisms, which are other mechanisms which may mask the action of the mechanism being assessed.
- Evidence snippets:
  - Snippet 1 (score: 0.557)
    > General mechanistic claim for efficacy. In formulating the general mechanistic claim for efficacy, the following questions should be addressed:
    > • What is the relevant population?
    > • What is the intervention or exposure level?
    > • What is the outcome and how is it measured? General mechanistic claim for external validity. In determining the general mechanistic claim concerning external validity, the following questions should be addressed:
    > • What is the target population? What is the study population?
    > • What is the intervention or exposure level in the target?
    > • What is the outcome and how is it measured in the target?
    > • What is the intervention or exposure level in the study?
    > • What is the outcome and how is it measured in the study?
    > It may be that existing evidence from clinical studies together with already wellestablished mechanisms is enough to establish the general mechanistic claim. In other cases, the existing evidence fails to establish causality, and it is necessary to identify and evaluate mechanistic studies. To this end, this chapter presents the following five-step strategy for gathering evidence of mechanisms:
    > 1. Identify: Identify a number of specific mechanism hypotheses. 2. Formulate: For each specific mechanism hypothesis, formulate a number of review questions. 3. Search: Use these review questions to search the literature. 4. Refine: Identify the evidence most relevant to the mechanism hypothesis by refining the results of this search. 5. Present. Present the evidence relevant to the mechanism hypothesis. This strategy is intended to help overcome some of the practical difficulties with identifying evidence of mechanisms-difficulties which may prevent appraisers from considering all the relevant evidence. Once this evidence of mechanisms has been identified, it can then be evaluated alongside the existing evidence of correlation from clinical studies, as explained in Chaps. 6 and 7.
    > The overall approach of this chapter is illustrated in Fig. 5.1. The five steps outlined above are explained in detail in the following sections.
  - Snippet 2 (score: 0.519)
    > Although ACE-inhibitors have proved beneficial for hypertension in many study populations, there remains the question of whether they are the optimal treatment in some distinct target population, such as African or Caribbean populations. In this case, it is necessary to determine the status of the following general mechanistic claim: the relevant hypertensive mechanisms in the study populations are sufficiently similar to the mechanisms in African or Caribbean populations. This general mechanistic claim can be evaluated by evaluating a more specific mechanism hypothesis, namely that African and Caribbean populations have a lower renin state. As we shall see in Chap. 6, there is some good mechanistic evidence in favour of this specific mechanism hypothesis, and this undermines the general mechanistic claim. This is why, instead, calcium channel blockers are the recommended antihypertensive treatment in African and Caribbean populations (Clarke et al. 2014).
    > There are two main ways to identify a specific mechanism hypothesis. First, a specific mechanism hypothesis may be proposed on the basis of published studies from the clinical study literature. If a clinical study establishes a correlation between a putative cause and effect, and the suggestion is that this correlation is causal, then the authors of such a study usually identify at least one possible mechanism hypothesis of the following form: It is plausible that mechanism with features F links the putative cause and effect in the study population. The study may also point out possible masking mechanisms (Illari 2011). Given this, the discussion section of a published paper that reports the results of a clinical study is a good place to look in order to locate a specific mechanism hypothesis.
  - Snippet 3 (score: 0.493)
    > The overall approach to gathering evidence of mechanisms of action. Each proposed mechanism of action, or partial description of proposed mechanism of action, is a specific mechanism hypothesis. But note that a specific mechanism hypothesis need not be a complete description of a mechanism.
    > Example: Specific mechanism hypotheses for determining efficacy.
    > Aspirin prevents heart disease via cyclooxygenase (COX) inhibition, and the mechanisms that underlie this prevention are established. However, aspirin also seems to reduce the incidence of some cancers. Here, the mechanisms are much less well understood. As Chan et al. (2011) write: "the mechanism of aspirin's antineoplastic effect is less clear, with substantial evidence supporting both COX-dependent and COX-independent mechanisms. Moreover, data supporting the importance of COX-dependent mechanisms are not entirely consistent concerning the relative importance of the COX-1 and COX-2 isoforms in carcinogenesis". In this quotation, the general mechanistic claim is that aspirin exhibits an antineoplastic effect. There are also a couple of more specific mechanism hypotheses, for example, that this antineoplastic effect is mediated by COX-dependent mechanisms. Evidence relating to these more specific mechanism hypotheses provides a way to determine the status of the general mechanistic claim.
    > External validity. In order to evaluate the general mechanistic claim that there is a mechanism in the target population sufficiently similar to the mechanism responsible for the correlation observed in the study population, specific mechanism hypotheses need to pertain to the mechanism of action. It is important to consider the possibility that the mechanism in the target population may contain further component mechanisms that counteract the mechanism of action in the study population and affect the extent of the correlation between the putative cause and effect. So one needs to ask, are there any masking mechanisms in the target population?
    > Example: Specific mechanism hypotheses for determining external validity.
    > According to NICE guidelines, treatment for hypertension should differ depending on ethnicity (NICE 2011). Although ACE-inhibitors have proved beneficial for hypertension in many study populations, there remains the question of whether they are the optimal treatment in some distinct target population, such as African or Caribbean populations.

### [2] A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection
- Authors: F. Langhauser, A. I. Casas, V. Dao, E. Guney, Jörg Menche et al.
- Year: 2018
- Venue: NPJ Systems Biology and Applications
- URL: https://www.semanticscholar.org/paper/44d6cd1d0dd2993b9a9f6b17e3f9705fb04892b8
- DOI: 10.1038/s41540-017-0039-7
- PMID: 29423274
- PMCID: 5799370
- Citations: 61
- Influential citations: 2
- Summary: It is shown that, based on this principle, a cardio-pulmonary drug can be surprisingly repurposed for a previously not recognised application as a direct neuroprotectant, and it is found that the cyclic GMP forming soluble guanylate cyclase becomes dysfunctional upon stroke but regains catalytic activity in the presence of specific activator compounds.
- Evidence snippets:
  - Snippet 1 (score: 0.523)
    > Drug discovery and development follows a relatively uniform path from mechanistic hypothesis, preclinical disease models to clinical validation. However, in recent years, a string of major drug developments have failed due to lack of efficacy. 1 One reason for this appears to reside in our current definitions of 'disease', i.e., mostly organ-based or by an apparent phenotype or symptom and not by an underlying mechanisms. However, without a validated pathomechanism no mechanism-based drugs can be developed and, therefore, rather surrogate parameters or risk factors are treated instead. Finding a rational approach towards mechanism-based disease definitions may therefore have a tremendous impact on drug discovery and medicine in general.
    > Using a data-driven approach, disease-disease networks (diseosome) have been constructed in which diseases are linked based on common molecular or regulatory mechanisms, 2 such as shared genetic associations, 2 protein interactions 3,4 or gene-disease interactions. 5 These diseasomes exhibit local clusters of diseases whose molecular relationships are well understood, but also unexpected clusters of surprisingly heterogeneous diseases. 3 Such clustering of disease phenotypes is likely due to underlying hidden common pathomechanisms. Importantly, these common mechanism clusters may provide previously unrecognized molecular definitions of these phenotypes and at the same time targets for mechanism-based drug discovery and repurposing.
    > Here we test the clinical validity of this approach by focusing on one cluster of highly prevalent combinations of vascular, neurological and metabolic disease phenotypes with high unmet medical need. Genetic evidence points to cGMP signaling as being part of its underlying pathomechanism. 5,6 We then inquire in a non-hypothesis-based manner using disease-disease networks based on common genetic origins, common protein interactions between disease genes, shared disease symptoms and disease co-morbidity for possible drug repurposing of cGMP modulators within this cluster.

### [3] SKiM-GPT: combining biomedical literature-based discovery with large language model hypothesis evaluation
- Authors: Jack Freeman, R. Millikin, Leo Xu, Ishaan Sharma, Bethany Moore et al.
- Year: 2025
- Venue: BMC Bioinformatics
- URL: https://www.semanticscholar.org/paper/ce7a6900a181708dba6ed2bf612d06b0be1d20b1
- DOI: 10.1186/s12859-025-06350-7
- PMID: 41408154
- PMCID: 12829140
- Summary: SKiM-GPT is introduced, a retrieval-augmented generation (RAG) system that combines SKiM’s co-occurrence search and retrieval with frontier LLMs to evaluate user- defined hypotheses, and achieves strong ordinal agreement with four expert biologists, demonstrating its ability to replicate expert judgment.
- Evidence snippets:
  - Snippet 1 (score: 0.513)
    > B Positive hypothesis condition. Without any provided abstracts ("No text"), when asked whether each drug "improves breast-cancer patient outcomes, " SKiM-GPT assigns positive scores (median = + 2), indicating that parametric (trained) memory is biased towards positive scores in these cases as expected ("parametric-knowledge leakage"). C Neutral hypothesis condition. Feeding synthetic abstracts that state no relationship exists between the drug and breast cancer patient outcomes increases scores for neutral hypotheses (median = + 2) for all drugs, indicating the model grounds its judgment in the supplied context rather than internal bias. D Negative hypothesis condition. Providing synthetic abstracts that refute drug efficacy results in increased scores for negative hypotheses (median = + 2). Together, panels B-D indicate that SKiM-GPT's scores mirror the sentiment of the abstracts rather than the LLM's training data SKiM-GPT correctly classified 19 of them, confirming 16 true drug-gene treatment links (positive scores) and correctly discarding three false positives (zero or negative scores). In the one case where SKiM-GPT was unable to correctly classify, the gene name SLN returned no relevant abstracts, as the abbreviation SLN can also stand for "sentinel lymph node" which is often a term associated with cancers.
    > Table 2. Assessment of SKiM-GPT's ability to remove false-positive hits in an LBD search. "Breast Cancer" was used as the A-term, a list of human genes as B-terms, and FDA-approved drugs as C-terms. The hypothesis "{C-term} treats {A-term} through its effect on {B-term}" was used to evaluate the top 20 hits ranked by p-value. For each SKiM A-B-C hit (column 1), SKiM-GPT scores the provided hypothesis from −2 (strongly refutes) to + 2 (strongly supports) after relevance filtering (column 2). Scores were classified as a true-positives (TP) or true-negatives (TN) based on current clinical or mechanistic evidence (column 3). The comments (column 4) contain context-specific notes written by human judges.

### [4] Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates
- Authors: P. N. Lalagkas, R. Melamed
- Year: 2024
- Venue: Human Genomics
- URL: https://www.semanticscholar.org/paper/5ed48d880dca9568260615e67fcb2cbd68c1bb3a
- DOI: 10.1186/s40246-024-00688-4
- PMID: 39538313
- PMCID: 11562851
- Citations: 1
- Summary: This work exploits the genetics of breast cancer and linked predisposing diseases to propose novel drug repurposing opportunities and develops a method to not only prioritize drugs for repurposing, but also to highlight shared etiology explaining repurposing.
- Evidence snippets:
  - Snippet 1 (score: 0.494)
    > Health conditions including high cholesterol and type 2 diabetes incur increased risk for breast cancer. Previous genetics research has supported a biological explanation: these diseases, which we will refer to as predisposing diseases, share genetic variation with breast cancer. Building on this, we hypothesize that finding the shared genetics between breast cancer and its predisposing diseases can help us discover new drugs for breast cancer. Specifically, we hypothesize that drugs approved for a predisposing disease and targeting its shared biology with breast cancer can treat the latter disease (Fig. 1A).
    > To test this hypothesis, we first search the scientific literature (epidemiological and statistical genetic studies) for diseases with genetic variation known to predispose Fig. 1 Outline of the approach. A. Tested hypothesis that a drug treating a health condition known to increase the risk for breast cancer and targets the shared biology of both conditions may also treat breast cancer. B-E. Proposed workflow to identify the most likely shared genes between breast cancer and a predisposing disease and connect them to drugs approved for the predisposing disease individuals to breast cancer. We find six such diseases [30][31][32][33][34] (Table 1).
    > Next, we aim to identify the shared genetics between each pair of breast cancer and a predisposing disease and connect them to drugs approved for the predisposing disease. We first use publicly available GWAS summary statistics data (Table 1) and a local genetic correlation analysis, to find the shared genetics (Fig. 1B-D). Then, for each predisposing disease, we use a network biology method to link the shared genes to canonical pathways, and similarly for all drugs treating the predisposing disease, we link their targets to the pathways (Fig. 1E). By finding drugs that target shared pathways, we both prioritize candidate drugs for repurposing for breast cancer and provide biological insights that support their effect in disease treatment.
    > Finally, we evaluate our list of candidate drugs. To do so, we compile a list of 583 drugs either in clinical trials (N = 451) or approved (N = 132) for breast cancer and test for enrichment within our candidate drugs.

### [5] Identification of Biomarkers for Breast Cancer Using Databases
- Authors: Eunhye Lee, A. Moon
- Year: 2016
- Venue: Journal of Cancer Prevention
- URL: https://www.semanticscholar.org/paper/9b33e30afc69380f4e374d30f12b9da9fc4ec013
- DOI: 10.15430/JCP.2016.21.4.235
- PMID: 28053957
- PMCID: 5207607
- Citations: 24
- Summary: This review summarizes the current databases which have been utilized for identification of biomarkers for breast cancer and would be beneficial to seeking appropriate strategies for diagnosis and treatment of breast cancer.
- Evidence snippets:
  - Snippet 1 (score: 0.492)
    > GEO dataset is used to identify biomarkers in specific drugs-resistance breast cancer. One of these is Lapatinib, a dual tyrosine kinase inhibitor that interferes with epidermal growth factor receptor and HER2/neu pathways by treating HER2-positive breast cancer. A study presented a novel strategy for researching the mechanism of laptinib-resistance breast cancers. 31 The oncogenic isoform of HER2, HER2∆16, is expressed with HER2 in nearly 50% of HER2 positive breast tumors, and HER2∆16 drives metastasis and resistance to drugs including tamoxifen and trastuzumab. 32 ][35][36] GEO database contributed to development of technologies and provided information on specific disease characteristics. The aim is enhancing, indexing, linking, searching and displaying capacity in order to permit more data mining. 37 The search engine enlarges the data and it can lead to understanding of unidentified relationships between variety of data types, facilitating novel hypothesis generation, or assisting in the analysis of available information.

### [6] Shared genetics between breast cancer and predisposing diseases identifies novel breast cancer treatment candidates
- Authors: P. N. Lalagkas, R. Melamed
- Year: 2024
- Venue: Research Square
- URL: https://www.semanticscholar.org/paper/3f4729126c3c31a61b5f2d6714f1632ac55aa27a
- DOI: 10.21203/rs.3.rs-4536370/v1
- PMID: 38947022
- PMCID: 11213186
- Citations: 3
- Summary: The genetics of breast cancer and linked predisposing diseases are exploited and a method to not only prioritize drug repurposing, but also to highlight shared etiology explaining repurposing is developed.
- Evidence snippets:
  - Snippet 1 (score: 0.490)
    > Health conditions including high cholesterol and type 2 diabetes incur increased risk for breast cancer.Previous genetics research has supported a biological explanation: these diseases, which we will refer to as predisposing diseases, share genetic variation with breast cancer.Building on this, we hypothesize that nding the shared genetics between breast cancer and its predisposing diseases can help us discover new drugs for breast cancer.Speci cally, we hypothesize that drugs approved for a predisposing disease and targeting its shared biology with breast cancer can treat the latter disease (Fig. 1A).
    > To test this hypothesis, we rst search the scienti c literature (epidemiological and statistical genetic studies) for diseases with genetic variation known to predispose individuals to breast cancer.We nd six such diseases (Table 1).
    > Next, we aim to identify the shared genetics between each pair of breast cancer and a predisposing disease and connect them to drugs approved for the predisposing disease.We rst use publicly available GWAS summary statistics data (Table 1) and a local genetic correlation analysis, to nd the shared genetics (Fig. 1B-D).Then, for each predisposing disease, we use a network biology method to link the shared genes to canonical pathways, and similarly for all drugs treating the predisposing disease, we link their targets to the pathways (Fig. 1E).By nding drugs that target shared pathways, we both prioritize candidate drugs for repurposing for breast cancer and provide biological insights that support their effect in disease treatment.
    > Finally, we evaluate our list of candidate drugs.To do so, we compile a list of 583 drugs either in clinical trials (N = 451) or approved (N = 132) for breast cancer and test for enrichment within our candidate drugs.

### [7] Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue
- Authors: Rossella Loria, P. Vici, F. S. Di Lisa, S. Soddu, M. Maugeri-Saccà et al.
- Year: 2022
- Venue: Frontiers in Oncology
- URL: https://www.semanticscholar.org/paper/cb43697914b25bbaa34869cbe04ffec4defb8ced
- DOI: 10.3389/fonc.2022.877380
- PMID: 35814399
- PMCID: 9259985
- Citations: 29
- Influential citations: 1
- Summary: The main cross-resistance events described in the diverse tumor types are summarized and insight into the molecular mechanisms involved in this process are provided to discuss the current challenges and provide perspectives for the research and development of strategies to overcome cross-Resistance.
- Evidence snippets:
  - Snippet 1 (score: 0.484)
    > The loss of target on HER2-targeted therapy is a widely recognized issue that has been discussed above for both BC (36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47) and GC (60)(61)(62). Provided that the knowledge of the underlying mechanisms is of paramount relevance, this evidence offers the opportunity to reconsider the strategies behind the design of RCTs. Indeed, many of these studies investigate the efficacy of new therapeutic approaches in metastatic/recurring patients stratified based on the molecular features of primary tumors. Interpreting the results generated from these trials could lead to sub-optimal clinical decision-making.
    > An emblematic example of this is the failure of the randomized phase II study WJOG7112G (T-ACT). The aim of the study was to explore the efficacy of paclitaxel with or without trastuzumab in 99 patients with HER2+ advanced GC who had disease progression after first-line chemotherapy with trastuzumab. Median PFS and OS were not significantly different between the two groups. In this case, loss of HER2 has been reported as a possible explanation for failure. Indeed, when HER2 status was re-evaluated in tumor biopsy specimens from 16 patients following disease progression, HER2 loss was observed in 11 patients (69%) (161).
    > In the specific case of HER2-targeted therapy, re-evaluating the HER2 status at the time of disease progression would be required (43). Supporting this, an ongoing phase II, open-label, single arm trial aimed at evaluating the efficacy and safety of T-Dxd in Western GC patients progressed with a trastuzumabcontaining regimen (DESTINY-Gastric02, NCT04014075) required patients to be re-tested for HER2 positivity before being treated with T-Dxd.
    > The Darwinian selection hypothesis assumes that cancer therapy selects pre-existing mutant cells that overtake the bulk cell population. However, this is a simplified mechanism that does not account for therapy resistance alone. In a more complicated scenario, genetic alterations and changes in the gene expression state often emerge under the selective pressure exerted

### [8] Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
- Authors: T. Honkanen, Milla E. K. Luukkainen, Antti Tikkanen, P. Karihtala, Markus J. Mäkinen et al.
- Year: 2021
- Venue: Breast Cancer Research and Treatment
- URL: https://www.semanticscholar.org/paper/f95f5f3008b0b18de39a4025a3d293e414e13fdc
- DOI: 10.1007/s10549-021-06447-6
- PMID: 34817749
- PMCID: 8763933
- Citations: 8
- Summary: The results suggest that the site of metastasis is associated with prognosis in HER2-positive breast cancer, highlighted by the poor prognosis of liver metastases.
- Evidence snippets:
  - Snippet 1 (score: 0.480)
    > Since immunology has a central role in HER2-positive breast cancer and targeted treatment acts through immunemediated mechanisms [5], we speculate that the presence of liver metastases would accordingly be associated with adverse prognosis and specific tumour immune profiles of the primary tumour.
    > In the current study, we tested this hypothesis by evaluating the prognosis and tumour immune cell profiles of 54 patients with metastatic HER2-positive breast cancer treated with trastuzumab containing regimens.

### [9] DiseaseConnect: a comprehensive web server for mechanism-based disease–disease connections
- Authors: Chun-Chi Liu, Y. Tseng, Wenyuan Li, Chia-Yu Wu, I. Mayzus et al.
- Year: 2014
- Venue: Nucleic Acids Research
- URL: https://www.semanticscholar.org/paper/164eec8e3e9af7dd3b1182e46be7577b90d44e1b
- DOI: 10.1093/nar/gku412
- PMID: 24895436
- PMCID: 4086092
- Citations: 100
- Influential citations: 6
- Summary: The DiseaseConnect is a web server for analysis and visualization of a comprehensive knowledge on mechanism-based disease connectivity that integrates comprehensive omics and literature data, including a large amount of gene expression data, Genome-Wide Association Studies catalog, and text-mined knowledge, to discover disease–disease connectivity via common molecular mechanisms.
- Evidence snippets:
  - Snippet 1 (score: 0.479)
    > After viewing all diseases and molecules related to a query disease, users can further explore the shared molecular mechanism(s) between two specific diseases by clicking an edge in the disease network. For example, when a user queries MM, the web server generates a disease-disease network. The user can then click the connection between MM and hemorrhagic disorders (HD) to view a network of shared genes and drugs between HD and MM. Figure 6A shows a small part of this network with the shared gene PSMB5 and the drug bortezomib. PSMB5 is a DEG for both HD and MM, and also has a GeneRIF association with MM. Bortezomib is a therapeutic proteasome inhibitor for treating MM, and targets PSMB5 (39). Interestingly, bortezomib can also treat HD (40), suggesting that shared disease genes can serve as good targets for drug repositioning strategies. Figure 6B shows another example network for the queried disease pair 'arthritis' and 'Crohn disease', both involve the tumor necrosis factor (TNF), based on the data sources GWAS and GeneRIF. Thalidomide is an immunomodulatory drug that targets TNF. Interestingly, thalidomide can treat both arthritis and Crohn diseases (41), supporting our hypothesis that diseases with a shared molecular mechanism are likely to be treated by the same drug. Another drug shown in Figure 6B, 'adalimumab', is known to target TNF and can treat arthritis, suggesting that it may also be effective for Crohn disease. In fact, this inference is confirmed independently by a recent report of Peters et al. (42). Also, several clinical trials about Adalimumab and Crohn disease (e.g. ClinicalTrials.gov ID: NCT01556672 and NCT01958827) are currently ongoing.

### [10] Large molecular systems landscape uncovers T cell trapping in human skin cancer
- Authors: Reyk Hillert, Anne Gieseler, Andreas Krusche, D. Humme, H.-J. Röwert-Huber et al.
- Year: 2016
- Venue: Scientific Reports
- URL: https://www.semanticscholar.org/paper/33de2062cfd1ed11b827368d31223ecb21fac495
- DOI: 10.1038/srep19012
- PMID: 26757895
- PMCID: 4725819
- Citations: 12
- Summary: Applying imaging cycler microscopy to analyse the immune contexture in a human skin cancer led to discovery of a mechanism of T cell trapping in the epidermis, which involves SPIKE, a network of suprabasal keratinocyte projections piercing and interconnecting CD8 T cells.
- Evidence snippets:
  - Snippet 1 (score: 0.473)
    > As shown before, inhibition of the lead proteins, e.g. in tumour cells results in disassembly of the corresponding protein clusters and loss of function 25 . Similar principles were demonstrated for amyothrophic lateral sclerosis (ALS) where CD16 (Fcgamma RIII) on human peripheral lymphocytes was identified as lead drug target 38 This protein was then confirmed as potential ALS drug target in a FcgammaRIII KO mouse model 28 and recently in a clinical phase II trial showing well tolerated downregulation of CD16 in ALS patients 29 with a halt of disease progression in 27% of the patients 30 . This empirical verification supports the toponome hypothesis that lead proteins controlling in vivo protein network topology and (dys)function can be predictive drug targets in chronic diseases and that the combinatorial geometry of protein networks at the target sites of the disease, as shown in present study, can provide important functional information on disease mechanisms.
    > ICM-based target identification and decoding of disease mechanisms in situ may thus complement current strategies for discovery of checkpoint controls as therapeutic target for reconstitution or enhancement of T cell activity against cancer 2,6,7,15,39-43 . The T cell trapping machinery may be a disease-specific robustness node for MF that ensures cancer progression by massively blocking cytotoxic T cells. As such it may be a target for therapeutic interventions that restore efficient anti-tumour immune responses.

### [11] Learning from our GWAS mistakes: from experimental design to scientific method
- Authors: Christophe Gerard Lambert, L. Black
- Year: 2012
- Venue: Biostatistics (Oxford, England)
- URL: https://www.semanticscholar.org/paper/7c92a4bffd527e9275e5dbc57e2037bc07fa93f9
- DOI: 10.1093/biostatistics/kxr055
- PMID: 22285994
- PMCID: 3297828
- Citations: 60
- Influential citations: 1
- Summary: In an era of large-scale biological research, questions are asked about the role of statistical analyses in advancing coherent theories of diseases and their mechanisms and for renewed appreciation of falsifiable hypotheses so that the authors can learn more from their best mistakes.
- Evidence snippets:
  - Snippet 1 (score: 0.472)
    > Collecting samples without specifying preliminary hypotheses leads to a frame of mind in which genetic assays are run without an experimental design that accounts explicitly for the hypotheses to be tested-in other words, not taking steps to randomize and so prevent biases in data. As with many large biological data collection efforts, GWAS are premised on an overarching hypothesis that a disease has a genetic cause, rather than many more granular hypotheses designed to challenge a causal theory of how a disease manifests. A GWAS might test a million null hypotheses that case-control status and a given genomic SNP are statistically independent over the population sample. The experiment to falsify these null hypotheses is an automated search for indications of association between genetic variants and disease status.
    > In the traditional scientific method, a hypothesis is a proposed explanation for a phenomenon, but scientists use the hypothesis to deduce additional predicted effects which, if observed, can corroborate the hypothesis but not prove it and, if not observed as predicted, can falsify the hypothesis. A single observation can falsify a traditional scientific hypothesis.
    > Such a hypothesis might describe a force or property common to all members of a population. A hypothesis of this sort must make universal claims in order to produce repeatable experiments; then a hypothesis tested by experimenting on a member of the population could be refuted for the entire population. If we abstract a hypothesis-forming process this way-"I have observed property X in a number of instances of A; I hypothesize that all other instances of A will have property X"-then the underlying premise is "All A's are effectively identical." If all A's are effectively identical, then we should accept that a corroborated or refuted hypothesis can inform us about the universe of A's. If A's are billiard balls, and we are looking at properties of how they transfer momentum on a billiard table, we would expect all instances of these A's to have the same properties.

### [12] Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
- Authors: Whitney P. Kirschbrown, Bei Wang, Ihsan Nijem, A. Ohtsu, P. Hoff et al.
- Year: 2019
- Venue: Cancer Chemotherapy and Pharmacology
- URL: https://www.semanticscholar.org/paper/a492f9caf28f09d00f0c32bddf510e6551559553
- DOI: 10.1007/s00280-019-03871-w
- PMID: 31183514
- PMCID: 6682857
- Citations: 10
- Summary: Pertuzumab exposure in JACOB was consistent with prior studies in advanced gastric cancer and breast cancer and appears to be an appropriate dose selection.
- Evidence snippets:
  - Snippet 1 (score: 0.471)
    > Tumor burden was ruled out as a potential mechanism in previously published popPK analyses [14]. Shed HER2 ECD was investigated within the JACOB study, as it was a significant covariate for the clearance of trastuzumab or ado-trastuzumab emtansine in MBC, although in these studies, the magnitude of impact was relatively small and not of clinical relevance [22,23]. In the JACOB study, baseline shed HER2 ECD levels were comparable to levels seen previously in breast cancer patients [F. Hoffmann-La Roche Ltd. Data on file] and there was no apparent relationship between baseline shed HER2 ECD and steady-state pertuzumab C min .
    > One promising non-target hypothesis is potential gastric protein leakage or protein-losing enteropathy (PLE) in patients with AGC. There is no direct clinical evidence for a relationship between PLE and the PK of mAbs; however, it is conceivable that PLE could be a driving factor in faster mAb clearance, given that GC is one of the disease states associated with PLE [24] and patients with PLE often develop hypoalbuminemia [25], which is known to be negatively correlated with mAb clearance [9,14,21,23]. Yang et al. [26] showed a decrease in murine IgG1 mAb area under the curve for 0-14 days from 1368 ± 255 to 594 ± 224 μg/mL/day in a murine model of colitis and PLE, providing preclinical support of this potential hypothesis.
    > Further studies are needed to identify first-line treatment options to improve patient outcomes in HER2-positive AGC and to better identify patients who might benefit from dual anti-HER2 targeted regimens [11]. Using methods beyond the current process for identifying HER2-positive AGC may compensate for the intratumoral heterogeneity observed in GC, which may have negatively impacted responses to targeted therapies in this and other trials [27,28].

### [13] De-risking clinical trial failure through mechanistic simulation
- Authors: Liam V. Brown, J. Wagg, R. Darley, Andy van Hateren, Tim Elliott et al.
- Year: 2022
- Venue: Immunotherapy Advances
- URL: https://www.semanticscholar.org/paper/231e07df51f980fbee090257094d32e95722e73e
- DOI: 10.1093/immadv/ltac017
- PMID: 36176591
- PMCID: 9514113
- Citations: 8
- Summary: A T-cell activation model was used to simulate the clinical trials of IMA901, a short-peptide cancer vaccine and predicted that responses are limited by peptide off-rates, peptide competition for dendritic cell (DC) binding, and DC migration times.
- Evidence snippets:
  - Snippet 1 (score: 0.468)
    > Despite their great predictive power, data-driven or statistical models do not generally contain a direct representation of the relevant biology and so are less well-suited to the study of hypothetical disease and drug mechanisms of action. Mechanistic models, which describe relevant biology with equations or simulations, are much better suited to in silico experimentation and hypothesis testing about mechanisms of action. Mechanistic model parameters usually have direct biological analogues, many of which can be controlled and tested in a clinical setting. One example of a mechanistic modelling study investigated the effect of bone morphogenetic protein treatment on paediatric disease of the bone [6], to understand the conditions under which disease severity is reduced by treatment and to stratify patients into responders, non-responders, and asymptomatic populations. An example applied to a clinical context predicted that short peptide cancer vaccines may preferentially select low-avidity T-cells, unless one optimises the dosage to reduce pMHC density on individual antigen-presenting dendritic cells (DCs) [7,8]. However, compared to data-driven or statistical modelling, mechanistic modelling is less frequently used in a clinical context; a Web of Knowledge search for papers containing 'machine learning clinical' published between 2017 and 2021 yielded 17450 results, versus 4778 for 'mechanistic model clinical'. The specific data-driven technique 'neural network model clinical' yields 7709 results. Nonetheless, mechanistic modelling is well-positioned to take advantage of the everincreasing quantitative understanding of disease biology and mechanisms. In this study, we will demonstrate how in silico simulation of clinical trials can be used to test a biological hypothesis in silico to understand the mechanisms of clinical failure and improve upon trial designs, rather than merely to fit models to data. We will focus on published clinical trials of a short-peptide cancer vaccine, as an example.
    > It has been proposed that the immune system may not launch an attack on tumours that it has the potential to recognise because it lacks sufficient activating stimuli, due, for example, to inhibition of effector or antigen-presenting cells within the tumour microenvironment and its draining lymph nodes, or to a lack of stimulating peptide antigens.

### [14] Systematic Analysis of Drug Targets Confirms Expression in Disease-Relevant Tissues
- Authors: Vinod Kumar, P. Sanseau, D. Simola, M. Hurle, Pankaj Agarwal
- Year: 2016
- Venue: Scientific Reports
- URL: https://www.semanticscholar.org/paper/afe28e41430a6602a7e0d0c0c1e94356bd3a534a
- DOI: 10.1038/srep36205
- PMID: 27824084
- PMCID: 5099936
- Citations: 24
- Summary: For 87% of gene-disease pairs, the target is expressed in a disease-affected tissue under healthy conditions, validates the importance of confirming expression of a novel drug target in an appropriate tissue for each disease indication and strengthens previous findings showing that targets of efficacious drugs should be expressed in relevant tissues under normal conditions.
- Evidence snippets:
  - Snippet 1 (score: 0.468)
    > It is commonly assumed that drug targets are expressed in tissues relevant to their indicated diseases, even under normal conditions. While multiple anecdotal cases support this hypothesis, a comprehensive study has not been performed to verify it. We conducted a systematic analysis to assess gene and protein expression for all targets of marketed and phase III drugs across a diverse collection of normal human tissues. For 87% of gene-disease pairs, the target is expressed in a disease-affected tissue under healthy conditions. This result validates the importance of confirming expression of a novel drug target in an appropriate tissue for each disease indication and strengthens previous findings showing that targets of efficacious drugs should be expressed in relevant tissues under normal conditions. Further characterization of the remaining 13% of gene-disease pairs revealed that most genes are expressed in a different tissue linked to another disease. Our analysis demonstrates the value of extensive tissue specific expression resources.both in terms of tissue and cell diversity as well as techniques used to measure gene expression.
    > Tissue specificity is an important aspect of many diseases that reflects the potentially different roles of proteins and pathways in diverse cell lineages 1 . Although a variety of diseases have tissue specific etiology, many diseases ultimately affect multiple organs and tissues 2 . Genes with tissue-specific patterns of expression and function play key roles in the physiological processes of complex organisms, and such genes are regarded to be intrinsic components of many human diseases 2 . In particular, gene activity has been reported to vary more greatly across organs or tissues within an individual than in the same tissue across individuals 3 .
    > Large scale genome-wide analysis of gene expression patterns has routinely been used to study human disease, as it enables the comprehensive comparison of different tissues [4][5][6] . To gain insight into the genes, pathways, and mechanisms affected by disease, most studies utilizing this approach have focused on comparing disease and non-disease states [4][5][6] . However, understanding a gene's normal pattern of expression in different healthy tissues provides a meaningful complementary perspective as well. For example, Lage et al. 7 presented the first quantitative study of the tissue-specific mRNA expression of over 2,000 Mendelian disease-associated genes and showed these genes are selectively expressed only in tissues where their disruption causes pathology-even under non-disease conditions. This finding supports an important mechanistic hypothesis

### [15] Integrative Systems Biology Resources and Approaches in Disease Analytics
- Authors: Marco Fernandes, H. Husi
- Year: 2019
- Venue: Systems Biology
- URL: https://www.semanticscholar.org/paper/b6360f094840c900e0116b69fe90daebe3161325
- DOI: 10.5772/INTECHOPEN.84834
- Citations: 1
- Summary: Several database resources, standalone and web-based tools applied in disease analytics workflows based in data-driven integration of outputs of multi-omic detection platforms are described.
- Evidence snippets:
  - Snippet 1 (score: 0.467)
    > Over the last decade the emergence of high-throughput screening platforms and the increase in availability of large-scale-omics data, as well as clinical data from electronic health records comprising phenotypic, therapeutic and environmental factors information opened the possibility to mechanistically understand diseases and diseases stages at the molecular level. Thereby, a great number of wealth data in many kidney and cardiovascular conditions was generated, however these findings were neither translated nor reached the clinical setting and are still enclosed in peer-reviewed literature and across general scope expression profiling databases. Simultaneously it has become apparent that the existing systems to integrate and correlate this data are either inadequate or non-existent. Due to the multi-factorial molecular phenotype of disease, it is evident that development of novel therapeutic and disease detection approaches should be based upon the study of the entire "System" simultaneously. Figure 1 gives a general overview in the fundamental difference between conventional and systems approaches, whereby in the context of conventional approaches a hypothesis is put forward that is assumed to be of importance in the disease or biological condition. This hypothesis is then tested and either validated or refuted based on the outcome of this hypothesis-driven methodology. Yet, it is obvious that it is easy to investigate any hypothesis and then choose the one that appears most correct, in the real world constraints such as time and financial resources do not allow for such an approach, and hypotheses are usually generated on a best-guess basis which can lead to a substantial amount of bias, resulting in skewed or partial insights and can often be misleading. In order to avoid such scenarios, research driven by the data itself rather than a hypothesis has been proposed a long time ago, but could not be properly implemented due to the lack of unbiased large-scale data or the ability to integrate disparate data in the first place. Additionally, a successful systems approach requires underlying prior knowledge, such as physicochemical parameters in how molecules interact with each other, what reactions they are involved in and other unconnected information. This knowledge has only slowly been accumulated through conventional research and has only over the last 10-15 years been available to such an extent where a systems approach became feasible. Data-driven systems biology-based diagnostic and prognostic models consisting of relevant panels of molecules-key branches of the cellular network, appear to more

### [16] Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents
- Authors: E. Efstathiou, A. Merseburger, A. Liew, K. Kurtyka, O. Panda et al.
- Year: 2024
- Venue: ESMO Open
- URL: https://www.semanticscholar.org/paper/fb81df75cf8787f5fec559887b77f5ba6d75837f
- DOI: 10.1016/j.esmoop.2024.103007
- PMID: 38744101
- PMCID: 11108859
- Citations: 1
- Summary: Human-led, AI-assisted large-scale qualitative language-based research revealed that cure was commonly discussed by academic researchers, HCPs, policymakers and the general public, especially in early-stage PC.
- Evidence snippets:
  - Snippet 1 (score: 0.466)
    > Janssen has asked Oxford PharmaGenesis to perform an innovative landscape review and linguistic analysis to identify and synthesize evidence that may support the hypothesis that use of the term cure is a reasonable target for patients with early-stage prostate cancer treated with Erleada.
    > To help focus the direction of this landscape review and linguistic analysis, three key research questions (KRQs) have been formulated after an initial scoping search.If we are not able to find sufficient information within prostate cancer, we will expand the search to other disease areas (eg, breast cancer, bladder cancer).

### [17] Machine Learning Analysis of Complex Networks in Hyperspherical Space
- Authors: M. Pereda, Ernesto Estrada
- Year: 2018
- Venue: arXiv: Physics and Society
- URL: https://www.semanticscholar.org/paper/a21feb31b53b4c5b59520b175884e15949582073
- Citations: 11
- Influential citations: 1
- Summary: This work considers a communicability function that accounts for the routes through which items flow on networks and uses one of the geometric parameters of this embedding, namely the angle between the position vectors of the nodes in the hyperspheres, to extract structural information from networks.
- Evidence snippets:
  - Snippet 1 (score: 0.465)
    > (as reported until 2007) in any other non-neurological disorder. Otherwise, it is grouped as "grey". This means that a gene grouped in the class of "neurological diseases was not known in 2007 to be involved also in "cancer". However, our clustering method groups together 88 genes involved in cancer with 69 genes involved in neurological disorders in the same cluster. Consequently, we formulate the hypothesis that: Hypothesis 1. Genes involved in neurological disorders which are in cluster 1 can also be involved in cancer due to certain similarity in their topological environment  in the gene-gene network.
    > In order to test this hypothesis we carried out a bibliographic search for all the genes in cluster 1 which were involved in neurological disorders to find whether they have been recently reported in cancer. Our search is based on the scientific literature published since 2006, a year before the year in which Goh et al. [27] paper was published. In Table 4 we report 19 genes that are known to be related to neurological diseases such as ataxia, Amyotrophic Lateral Sclerosis (ALS), Parkinson, epilepsy and Charcot-Marie-Tooth disease, which are in cluster 1. In addition, in the most recent literature we have found evidences of the involvement of these genes in breast, colorectal, ovarian, lung, prostate, and other types of cancer. Although our search has not being exhaustive, the current findings point out to the fact that the clusters found in this work may contain important biological information. In particular, that genes clustered in the same group but having involvement in different diseases may have some "promiscuity" in the sense of being responsible for several diseases, such as the ones reported in Table 4 for neurological diseases and cancer (all the references for the new findings are reported in a Supplementary Information accompanying this paper). We should point out that there are other 50 genes in this cluster which were reported as involved in neurological diseases and for which we did not find any connection with cancer. These genes could be target of experimental search for involvement in different types of cancer also confirming our hypothesis 1.  Table 4: List of genes which were grouped in cluster 1 due to their involvement in neurological diseases and which have been recently reported to be involve in cancer as correspond to 37% of genes in cluster 1.
    > The second example is

### [18] An Application of Fuzzy Prototypes to the Diagnosis and Treatment of Fuzzy Diseases
- Authors: Rubén Romero-Córdoba, J. Olivas, F. P. Romero, Francisco Alonso-Gómez, J. Serrano-Guerrero
- Year: 2017
- Venue: International Journal of Intelligent Systems
- URL: https://www.semanticscholar.org/paper/36623f163659f9e4d1cf968252e10e36faa19676
- DOI: 10.1002/int.21836
- Citations: 20
- Influential citations: 1
- Summary: A reasoning method that uses theories about conceptual categorization from the psychology, pattern recognition, and Zadeh's prototypes has been designed and satisfactory results in the evaluation of patients were obtained.
- Evidence snippets:
  - Snippet 1 (score: 0.465)
    > Medical reasoning, as well as some kinds of scientific and technical reasoning, follows a logic of conjectures and refutations; that is, the physician from his encounter with the patient starts with different hypothesis which can be verified, or on the contrary, be refuted. If the hypothesis is refuted by experimental facts, it is subsequently replaced by other hypotheses that are better adapted to the facts. Thus, for each disease you can have, on the one hand, a degree of confirmation (i.e., the degree to which the evidence supports the hypothesis under consideration) and, on the other hand, a degree of refutation (i.e., the degree to the facts refute the hypothesis). The result of combining these two factors is the degree of credibility of this hypothesis. Therefore, each disease being considered by the system includes a set of facts that confirm or falsify. The logic model to present the factors confirmation, falsification, and credibility is based on fuzzy techniques, in extensions of the theory of prototypes of Zadeh. 8 ccording to the prototype resemblance theory of disease, 29 the nosological class that comprises such fuzzy human conditions as diseases cannot be based on and represented by, a classical, reductively definable concept of disease. Nevertheless, the class of diseases can be defined as an irreducible category that is constituted by some prototypes to which the remaining members of the category, the diseases, are similar to different extents. It is possible to consider that ideal types prototypically describe a disease, but in fact only approximate the ideal to a degree. Some kinds of diseases show some kinds of uncertainty or vagueness associated with the fulfillment of this ideal. Therefore, to develop this theory it is essential to measure the similarity between a member of a category and its prototype.
    > Fuzzy deformable prototypes (from now on FDPs) can provide an adequate formal framework for working with this idea.

## Notes

- This provider combines `search_papers_by_relevance` with `snippet_search`.
- No synthesis or second-stage model call is performed.
